Identifying Genetic Subtypes May Aid Future Treatment Decisions in Lymphoma
Although the findings need to be tested further in clinical trials, this could lead to new targeted therapies with fewer toxicities for patients.
Although the findings need to be tested further in clinical trials, this could lead to new targeted therapies with fewer toxicities for patients.
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
Still unresolved is whether to screen the general population for MGUS, a largely asymptomatic condition usually noted during routine blood testing.
Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.
While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.
Whether cryosurgery or cryoablation will prove a viable alternative to lumpectomy — the standard of care for women with early breast cancer — remains uncertain.
A pooled analysis of 3 combination drug regimens used to treat refractory/relapsed multiple myeloma reaffirms their safety, but does little to distinguish which approach works best.
For Merkel-cell cancers—the deadliest and rarest type—there are no approved drugs once surgery and radiation fail.
Physicians and cancer organizations suggest more research is needed before the Epi proColon blood test becomes a standard screening approach.
Ongoing litigation over patent protection and concern about drug labeling guidance and potential safety issues have slowed the availability of biosimilars.